好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Meta-analysis of ICI-induced Encephalitis: Differentiating Paraneoplastic from Pure Iatrogenic Cases
Autoimmune Neurology
P6 - Poster Session 6 (5:00 PM-6:00 PM)
2-004

To compare the treatment response and overall prognosis of pure iatrogenic versus paraneoplastic immune checkpoint inhibitor (ICI)-induced encephalitis.

ICIs offer favorable outcomes over conventional cytotoxic therapies but can also cause neurologic immune-related adverse events (irAE-Ns), which either arise through de novo induction of an anti-neural immune response or unmasking of a latent paraneoplastic process. As existing literature fails to differentiate these two etiologies despite their distinct prognoses, we compared neurologic response to treatment between pure iatrogenic and iatrogenic/paraneoplastic ICI-induced encephalitis.

Inclusion criteria included ICI encephalitis-related conditions. Cases were categorized using the 2021 Paraneoplastic Neurologic Syndrome (PNS) Care Score by clinical phenotype, antibody type, high-risk cancer presence, and follow-up time. Definite/probable PNS scores indicated iatrogenic/paraneoplastic cases; possible/non-PNS scores indicated iatrogenic cases. Neurologic response was defined as complete, partial, and no response/worsening. These were compared using a chi-squared test to determine significance and dichotomized into favorable (complete or partial) and unfavorable neurologic responses (no response or worsening).

We conducted a meta-analysis of 185 articles documenting ICI-encephalitis and encephalitis-related cases (2011–May 2025; PubMed/Web of Science). The cohort included 309 patients (168 males, 127 females; median age 65.0 years). 122 patients had neuronal autoantibodies (most commonly anti-Hu and anti-Ma2). Applying the PNS score revealed 169 patients (55%) had probable or definite paraneoplastic origin triggered by ICIs (iatrogenic/paraneoplastic) while 140 patients (45%) were not paraneoplastic (pure iatrogenic encephalitis induced by ICIs). Patients primarily received anti-PD1 (47%), anti-PDL1 (29%), combination therapy (20%), or anti-CTLA4 (4%). Pure iatrogenic cases showed significantly more favorable neurologic responses than iatrogenic/paraneoplastic cases (86% vs 62%, p=0.00003).

Accurate diagnosis of PNS is essential—ICIs induce two distinctive patterns of encephalitis: pure iatrogenic with a favorable prognosis or paraneoplastic with a guarded prognosis. Applying the PNS score to patients with ICI-induced irAE-Ns is crucial for proper prognostication, informing clinical decision-making, and optimizing patient management.

Authors/Disclosures
Davina Patel, MS
PRESENTER
Miss Patel has nothing to disclose.
Claire Yin Ms. Yin has nothing to disclose.
Rohit Rao, MD, PhD Dr. Rao has nothing to disclose.
Talal Alumri, MD Dr. Alumri has nothing to disclose.
Hesham A. Abboud, MD (University Hospitals Cleveland Medical Center) Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech . Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alpine Pharma. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cycle Pharma. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axonics. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Abboud has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Horizon. Dr. Abboud has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TG Therapeutics. The institution of Dr. Abboud has received research support from Genentech . The institution of Dr. Abboud has received research support from Novartis. The institution of Dr. Abboud has received research support from BMS. The institution of Dr. Abboud has received research support from Sanofi-Genzyme. The institution of Dr. Abboud has received research support from The Guthy-Jackson Charitable Foundation. The institution of Dr. Abboud has received research support from UCB. Dr. Abboud has received publishing royalties from a publication relating to health care.